Erik Manting, PhD has worked for a number of years as a post-doctoral researcher in the field of immunology before making a career switch to banking in 2001. He has more than 15 years of experience in different commercial and management roles in banking, including five years as Executive Director Corporate Finance at Kempen & Co. He acted as CEO of DCPrime BV since March 2018 and was appointed as CEO of Immunicum AB in March 2021, following the merger between both companies in December 2020. The combined company was renamed Mendus in June 2022. Dr Manting holds a MSc in Medical Biology and a PhD in Molecular Microbiology from the University of Groningen.

Jayant Narang, MD, is a radiologist by training. He joined Takeda Pharmaceuticals 3 years ago in March 2022 as Senior Medical Director and Clinical Oncology Imaging Lead. He has been in the industry for last 15 years.

Before Takeda, Dr Narang served as Head of hematology and oncology at Calyx, an imaging CRO. He was at Calyx (Parexel/Perceptive) from 2017 to 2022 leading several Oncology and Hematology trials as scientific lead in Parexel. He provided oversight and medical imaging input to these trials and led several of these trials to regulatory approvals. He has a special interest and extensive experience in solid tumors, Lymphoma, Multiple Myeloma, and Chronic Lymphocytic Leukemia. He has expertise in trial-specific modifications to commonly used oncology assessment criteria in order to correlate to drug effect evaluated through imaging and clinical data to derive surrogate endpoints. Before Parexel he was a staff radiologist, reading as an independent reviewer at Virtualscopics/Biotelemetry and did reads for hundreds of clinical trials. Before coming to the industry, Dr Narang was a practicing academic radiologist at Nanavati Hospital Mumbai, India with a special interest in MRI. Dr.Narang has published numerous peer-reviewed articles and presented at several international conferences.

Dr Narang has special interests in the application of novel imaging biomarkers in clinical trials such as the use of novel PET tracers, radiomics, tumor growth kinetics and AI/ML to derisk and accelerate oncology drug development.”

Adi Mohanty is an experienced biotech business leader with a track record of successful product development and approval. He is CEO of Biora Therapeutics, Inc., a clinical- stage biotech company developing smart pill-based therapeutics platforms. Previously, Adi served as CEO of BioTime, a stem cell therapy company. Prior to that, he held several executive positions at Shire, spanning global technical operations, product development, and commercial operations, culminating in the role of President, Regenerative Medicine. He was previously a vice president at Transkaryotic Therapies, which was acquired by Shire PLC. Earlier in his career, he held a variety of management positions in the bioscience division of Baxter Healthcare. Mr. Mohanty received his MBA at Saint Mary’s College, California and he holds a Master of Science in Chemical Engineering from Clarkson University.

Kissondra is the Oncology PRC Lead in the Clinical Center of Excellence at BMS, where she oversees the scientific rigor and quality of all clinical documents within the BMS oncology portfolio. With 10 years of experience in clinical research, she has held roles in Innovation and Digital Health, Study Optimization, and served as the Trial Digitalization and Foundational Portfolio Lead supporting R&D’s core and emerging business goals through the Drug Development’s Innovation Program. She has extensive experience in solution development with both internal and external partners and is passionate about leading cross-functional collaborations to challenge traditional ways of working.

Kissondra held roles at Moffitt Cancer Center, the University of South Florida, and Intezyne, and she has volunteered for over 4,000 hours at healthcare facilities. In addition, she holds an MBA, MS in Biotechnology, and graduate certificate in Intellectual Property.

Gaurav is a co-inventor of Piezo’s novel platform and founding CEO of Piezo Therapeutics. Prior to Piezo, he’s served in a variety of roles at Moelis and Company, Capital One, and Elevance Health. He’s a published scientist with a background in drug delivery and synthetic biology. He holds a BS in Industrial and Systems Engineering from Georgia Institute of Technology.

Dr Shawn Fu is currently the Head of CorpDev and Strategy at SonoThera, a venture backed non-viral, ultrasound based gene therapy company. Prior to joining SonoThera, Shawn was a Vice President at Vertex Ventures HC focusing on platform technologies and genetic medicines where he led investments and held board positions across both biotech & medtech opportunities, including, among others, SonoThera, Allay Therapeutics, and SpyGlass Therapeutics. Previously, Shawn also served as Vice President on JP Morgan’s Equity Research desk covering large / SMid Cap Biotech.

Dr Fu obtained his medical degree at UT Southwestern Medical School and his bachelor’s in biology/economics at Duke University.

Jaspreet Arora, PhD, is currently the Director of Business Development at Seran. He has 8 years' experience in drug product development with a recent NDA submission and approval for Leqselvi (Deuruxolitinib). He has early to late-stage experience including commercial readiness and IND/NDA writing. His oral solid dosage form expertise includes formulation and analytical characterization with a focus on material science. Previously Jaspreet worked for Concert Pharma (acquired by Sun Pharma) and Lonza-Bend (Bend Research). Jaspreet has a PhD in Chemical Engineering from Tulane University and a bachelor’s degree in biotechnology from Panjab University. Jaspreet applies his technical experience and training to understand client problem statements and support tailored solutions that fit clients' needs.

Yogev Debbi is the co-founder and CEO of Mana.bio. Previously, after working for years at the tech industry at Intel Corporation (Nasdaq: INTC), he co-founded and was the COO of Genome Compiler, a software gene editing company which was acquired by Twist Bioscience (Nasdaq: TWST), where he then led Twist's Israel R&D center through its IPO. Yogev brings deep expertise in launching and scaling successful bioengineering startups. As a repeat entrepreneur, Yogev is excited about the integration of software and biology and he is focused on leveraging the integration of the two fields to create disruptive technologies to positively impact human health.

Rick Aldridge, MBChB is a Managing Director in Lazard’s Global Healthcare team focused on the Life Sciences Sector.

He joined Lazard in 2015 from Bank of America Merrill Lynch where he was an equity research analyst in the European Pharmaceutical team with lead coverage in the mid-cap biopharma space. The team was top-ranked in the Institutional Investor survey in 2013, 2014 and 2015.

Dr Aldridge is a Chartered Accountant (CA), Chartered Tax Advisor (CTA) and a member of the CFA institute. He holds an MBChB (Medicine) from the University of Edinburgh and a Masters (Dist) in Economic History from the University of Glasgow.